ERBB2 and breast carcinoma: Thus, we herein explore for the first time the individual and combined effects of DA and PD-L1 inhibitor (BMS-202); a small molecule that blocks the interaction between PD-1 and PD-L1, on selected parameters in two HER2-positive human breast cancer cell lines.